• About us
• Contact

Advertisement

Organisation › Details

Fujifilm Diosynth Biologics Manufacturing Site in Hillerød, Denmark

FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization partner for the development and manufacture of biologics, vaccines, cell and gene therapies, and oncolytic viruses. The company operates a global network with major locations in the United States of America, the United Kingdom and Denmark and it is building a new manufacturing site in Holly Springs, North Carolina, USA. FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacture of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary Paveway™ microbial and Apollo™X cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. *

 

	Start	2019-03-12 renamed
	Group	Fujifilm (Group)
	Industry	contract manufacturing (biologicals)
	Industry 2	biopharmaceutical
	Region	Hillerød
	Country	Denmark
	Street	1 Biogen Alle
	City	3400 Hillerød
	Tel	+45-7741-6000
		Address record changed: 2020-12-02
Basic data	Employees	E: 501 to 1,000 (2019-03-05)
		* Document for »About Section«: Fujifilm Diosynth Biotechnologies UK Ltd.. (8/20/24). "Press Release: Fujifilm Diosynth Biotechnologies Celebrates Opening of Billingham, UK Microbial Manufacturing Facility". Billingham.
		Record changed: 2024-08-28

Advertisement

More documents for Fujifilm (Group)

• [1] Fujifilm Diosynth Biotechnologies UK Ltd.. (8/20/24). "Press Release: Fujifilm Diosynth Biotechnologies Celebrates Opening of Billingham, UK Microbial Manufacturing Facility". Billingham....
• [2] Fujifilm Diosynth Biotechnologies UK Ltd.. (12/2/21). "Press Release: Fujifilm Diosynth Biotechnologies Confirms £400 Million Investment Plans to Create the Largest Multi-modal Biopharmaceutical Manufacturing Site in the United Kingdom". Billingham....
• [3] Rentschler Biopharma SE. (10/28/21). "Press Release: Rentschler Biopharma Appoints Dr. Robert Panting as General Manager of Rentschler ATMP Ltd., Center of Excellence for Cell and Gene Therapy". Laupheim & Stevenage....
• [4] TreeFrog Therapeutics SAS. (2/5/20). "Press Release: TreeFrog Therapeutics Brings in Senior Profiles to Drive the Advent of High-quality and Affordable Allogenic Cell Therapies". Bordeaux....
• [5] Selexis S.A.. (1/9/20). "Press Release: Selexis Promotes Dr. Yemi Onakunle to Chief Business Officer". Geneva....
• [6] Fujifilm Corporation. (11/14/19). "Press Release: Fujifilm Announces Expansion of its Biopharmaceutical Contract Development and Manufacturing Business". Tokyo....
• [7] Genovis AB. (5/16/19). "Press Release: Genovis Signs Distribution Agreement with Fujifilm Wako Pure Chemical for Japan, Taiwan and Singapore Markets"....
• [8] Biogen Inc.. (3/12/19). "Press Release: Biogen Enters Into an Agreement to Sell Its Large-Scale Biologics Manufacturing Site in Hillerød, Denmark to Fujifilm". Cambridge....
• [9] Fujifilm Irvine Scientific, Inc.. (1/2/19). "Press Release: Accelerating the Growth of the Cell Culture Media Business. Leading Cell Culture Media Company Changes Name to »Fujifilm Irvine Scientific, Inc.«"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.